Antifungal Canesten unidy cream 30g 1% Canesten
CANESTEN UNIDIE 1% CREMA
active ingredients
1% cream 100 g cream contain: active ingredient: bifonazole 1 g Excipients with known effects: cetilstearilic alcohol, monostearate sorbitan, polysorbate 60, benzilic alcohol. For the full list of excipients see 6.1Excellent
1% cream monostearate sorbitan polysorbed 60 sperm cetilsteari alcohol octildocanolo alcohol benzig purified waterTherapeutic indications
Treatment of dermatomycosis supported by dermatophytes, by saccaromycetes, by other pathogenic fungi: mycosis of the foot and of the hand, mycosis of the trunk (tinea corporis), mycosis of the skin folds (tinea inguinalis), onicomicosi, pityriasis versicolor, candid superficial.Contraindications
Hypersensitivity to the active ingredient or any of the excipients listed in the paragraph 6.1.Population
For the purposes of complete healing, the controlled and sufficiently prolonged use of Canesten Unidie is indispensable. However, it is recommended not to stop therapy immediately after the disappearance of acute flogistic manifestations and subjective symptomatology, but to stick to the following average treatment times, depending on the type of infection, extension and location of the infection itself:Indications | Duration of treatment |
Mycosis of the foot (Tinea pedis, tinea pedum interdigitalis) | 3 weeks |
Mycosis of the trunk, hands and skin folds (Tinea corporis, tinea manuum, tinea inguinalis) | 2-3 weeks |
Pityriasis versicolor | 2 weeks |
Surface Candidosis | 2-4 weeks |
Conservation
No particular conditionWarnings
The use, especially if prolonged, of products for topical use, can give rise to phenomena of sensitization that manifest with redness and itching; in such case, it is necessary to stop treatment and establish suitable therapy. We will also be involved in the development of resistant microorganisms. Patients with proven hypersensitivity reactions to other imidazolic antifungals (e.g. econazole, clotrimazole, miconazole) must use medicinal products containing bifonazole with caution. Canesten Unidie contains cetilstearilic alcohol: can cause local skin reactions (e.g. contact dermatitis). Canesten Unidie contains monostearate sorbitan: can cause local skin reactions (e.g. contact dermatitis). Canesten Unidie contains 20mg/g benzyl alcohol: - can cause allergic reactions; - can cause slight local irritation. Canesten Unidie contains polysorbed 60: can cause local skin reactions (e.g. contact dermatitis). Avoid contact with eyes Do not ingestInteractions
The available data suggest a possible interaction between bifonazole by topical and warfarin with increased protrombine time. If Canesten Unidie is used in patients with warfarin therapy, these should be properly monitored.Effects
The following adverse reactions arise from post-marketing spontaneous signals and it is not possible to define the frequency. Systemic pathologies and conditions for administration Pain in administration, peripheral edema (in administration). Pathologies of skin and subcutaneous tissue Contact dermatitis, allergic dermatitis, erythema, itching, rash, hives, hives, skin exfoliation, eczema, dry skin, irritation of the skin, skin maceration, burning sensation. These side effects are reversible after suspension of treatment. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.Overdosing
There are no overdose cases.Pregnancy Preclinical safety data and pharmacokinetics data on man, give no indication of the effects for the mother and child when using bifonazole during pregnancy (see paragraph 5.3). It is better to avoid the use of bifonazole during the first trimester of pregnancy. Food Excretion in milk was studied in animals. The pharmacodynamic/toxicology data available in animals have shown that bifonazole and its metabolites pass into breast milk (see paragraph 5.3). It is not known whether bifonazole is excreted in human milk. Breastfeeding should be stopped during treatment with bifonazole. Fertility Preclinical studies have not shown impairment of male or female fertility (see paragraph 5.3)
Source: Farmadati
- Deductible product
- Yes
026045029
20 Items
New
No reviews